Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective StudyElena Bolzacchini, Francesco Dentali, Luca Galli et al.|Clinical Genitourinary Cancer|2019Cited by 7